2019, Number 2
<< Back Next >>
Dermatología Cosmética, Médica y Quirúrgica 2019; 17 (2)
Expression of Ki67 in Primary and Recurrent Basocellular Carcinoma
López GLA, Vega MME, Ortiz HC, Lara TC, Cuevas GJC
Language: Spanish
References: 19
Page: 84-88
PDF size: 242.74 Kb.
ABSTRACT
Introduction: basal cell carcinoma (BCC) is the most common
type of skin cancer and originated from the basal layer of
the epidermis and/or appendages, is characterized by a high
degree of local malignancy as well as a tenfold risk of developing
a second primary.
Material and methods: a cross-sectional study was
carried out in cases with confirmed diagnosis of bcc in any of
its histological forms and that presented recurrence. Samples
were collected from the Department of Dermatopathology of
the General Hospital Dr. Manuel Gea González, in Mexico City.
The data was separated in two groups bcc primary (n = 7) and
with recurrence (n = 7). Immunohistochemistry (Ki67) was performed
and results were evaluated semi-quantitatively by the
assessing expression of the antibody expressed in percentage.
Results: from a total of 14 cases, a female/man rate 4:3 was
observed with a mean age of 73 years (± 59 to 88 years), the
mean evolution time between the onset of the primary and recurrence
was 38.5 months. In the present study, the expression
obtained from Ki67 showed a difference in the topography,
in cases of recurrence it presents with a generalized predominance
in comparison with the cases of primary lesion where it
was observed peripherally.
Conclusion: the expression of Ki67 was able to establish a
difference between primary and recurrent BCC. We propose to
carry out studies with a major number of cases as well as ihc
markers to establish a diagnostic panel between primary and
recurrent lesions.
REFERENCES
Editorial, Basal cell carcinoma: what you need to kno, J Adv Pract Oncol 2015; 6:283-4.
Fecher LA y Sharfman WH, Advanced basal cell carcinoma, the hedgehog pathway, and treatment options: role of smoothened inhibitors, Biologics 2015; 9:129-40.
Feller L, Khammissa RA, Kramer B, Altini M y Lemmer J, Basal cell carcinoma, squamous cell carcinoma and melanoma of the head and face, Head Face Med 2016; 12:11.
Kumar S, Mahajan BB, Kaur S, Yadav A, Singh N y Singh A, A study of basal cell carcinoma in South Asians for risk factor and clinicopathological characterization: a hospital based study, J Skin Cancer 2014; 173582.
Marzuka AG y Book SE, Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management, Yale J Biol Med 2015; 88:167-79.
Szewczyk MP, Pazdrowski J, Dan´czak-Pazdrowska A, Golusin´ski P, Majchrzak E, Luczewski L et al., Analysis of selected recurrence risk factors after treatment of head and neck basal cell carcinoma, Postepy Dermatol Alergol 2014; 31:146-51.
Iljin A, Zielin´ski T, Antoszewski B y Sporny S, Clinicopathological analysis of recurrent basal cell carcinoma of the eyelid, Postepy Dermatol Alergol 2016; 33:42-6.
Stacey SN, Helgason H, Gudjonsson SA, Thorleifsson G, Zink F, Sigurdsson A et al., New basal cell carcinoma susceptibility loci, Nat Commun 2015; 6:6825.
Armstrong LT, Magnusson MR y Guppy MP, The role of embryologic fusion planes in the invasiveness and recurrence of basal cell carcinoma: a classic mix-up of causation and correlation, Plast Reconstr Surg Glob Open 2016; 3:582.
Ghita MA, Caruntu C, Rosca AE, Kaleshi H, Caruntu A, Moraru L et al., Reflectance confocal microscopy and dermoscopy for in vivo, non-invasive skin imaging of superficial basal cell carcinoma, Oncol Lett 2016; 11:3019-24.
Nielsen PS, Riber-Hansen R, Jensen TO, Schmidt H y Steiniche T, Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage i/ii melanoma, Mod Pathol 2013; 26:404-13.
Vega Memije ME, Luna EM, De Almeida OP, Taylor AM y Cuevas González JC, Immunohistochemistry panel for differential diagnosis of basal cell carcinoma and trichoblastoma, Int J Trichology 2014; 6:40-4.
Savoia P, Deboli T, Previgliano A y Broganelli P, Usefulness of photodynamic therapy as a possible therapeutic alternative in the treatment of basal cell carcinoma, Int J Mol Sci 2015; 16:23300-17.
Cardona-Hernández MA, Peniche-Castellanos A, Fierro-Arias L, García- Guerrero VA y Mercadillo P, Prevalencia de patrones histológicos agresivos de carcinoma basocelular en pacientes menores de 40 años. Experiencia de cinco años en el Hospital General de México, Dermatol Rev Mex 2013; 57:149-54.
Lewin JM y Carucci JA, Advances in the management of basal cell carcinoma. F1000Prime Rep 2015; 7:53.
Luz FB, Ferron C y Cardoso GP, Surgical treatment of basal cell carcinoma: an algorithm based on the literature, An Bras Dermatol, 2015; 90:377-83.
Porceddu SV, Prognostic factors and the role of adjuvant radiation therapy in non-melanoma skin cancer of the head and neck, Am Soc Clin Oncol Educ Book 2015; 513:8.
Bartosˇ V, Pokorný D, Zacharová O, Haluska P, Doboszová J, Kullová M et al., Recurrent basal cell carcinoma: a clinicopathological study and evaluation of histomorphological findings in primary and recurrent lesions, Acta Dermatovenerol Alp Pannonica Adriat 2011; 20:67-75.
Cuevas-González MV, Vega-Memije ME, Cuevas-González JC, García- Vázquez FJ, Cháirez-Atienzo P y Ávila-Valdez R, Expresión de cd34, Ki-67, p53 y citoqueratina ae1/ae3 en el carcinoma basocelular sólido y adenoideo, Dermatol Rev Mex 2016; 60:311-8.
Full text